Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalSTU:IC7 80 Debt-to-EBITDA is 3.48 as of Jun. 2026, which is 22% below its 10-year median of 4.46. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 473 Medical Devices & Instruments companies, ICU Medical ranks worse than 80.76% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ICU Medical's Debt-to-EBITDA or its related term are showing as below:
STU:IC7'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.19 Med: 4.46 Max: 9.05
Current: 4.48
During the past 13 years, the highest Debt-to-EBITDA Ratio of ICU Medical was 9.05. The lowest was 0.19. And the median was 4.46.
STU:IC7's Debt-to-EBITDA is ranked worse than 80.76% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs STU:IC7: 4.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ICU Medical Debt-to-EBITDA Related Terms
ICU Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ICU Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IC7 vs NVST, MMSI, MMED: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ICU Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
ICU Medical (STU:IC7) has a Debt-to-EBITDA of 3.48 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ICU Medical. This is 22% below median its historical median of 4.46. Over the past decade, ICU Medical's Debt-to-EBITDA has ranged from 0.19 to 9.05. According to the industry distribution chart, ICU Medical ranks #382 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 80.8%.
Is ICU Medical's Debt-to-EBITDA too high?
ICU Medical's current Debt-to-EBITDA of 3.48 is 22% below median its 10-year median of 4.46. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 9.05. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. ICU Medical's value of 3.48 is 114.8% above this industry median. Based on the distribution chart, ICU Medical ranks #382 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Debt-to-EBITDA compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #382 out of 473 companies for Debt-to-EBITDA. This places ICU Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. ICU Medical's value of 3.48 is 114.8% above this benchmark. Historically, ICU Medical's own Debt-to-EBITDA has ranged from 0.19 to 9.05 over the past decade. While the company's 10-year median is 4.46 vs. the industry median of 1.62, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current Debt-to-EBITDA of 3.48 is 114.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ICU Medical. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current Debt-to-EBITDA is 3.48, which is 22% below median its own 10-year median of 4.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current Debt-to-EBITDA is 3.48, which is 22% below median its 10-year median of 4.46 and 114.8% above the Medical Devices & Instruments industry median of 1.62. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current Debt-to-EBITDA is 3.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (STU:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for STU:IC7:
Debt-to-EBITDA: 3.48 (22% below median its 10-year median of 4.46)
GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
Industry Position: 114.8% above the Medical Devices & Instruments median (#382 of 473)
No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score
Get the complete analysis for STU:IC7
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IC7 has been successfully added to your 
